U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07734766) titled 'Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery' on July 24.
Brief Summary: This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose tumors show a histopathological feature known as tumor budding, which is associated with a higher risk of postoperative recurrence.
Ebastine is a second-generation antihistamine approved for allergic conditions. Preclinical studies have shown that ebastine also inhibits FAK signaling, a pathway implic...